Patent ID: 11945807
Assignee: EISAI R&D MANAGEMENT CO., LTD
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C  G | IPC A  C  G

Claim 16:
17. A compound of Formula (VIII-A):, or a pharmaceutically acceptable salt thereof,
wherein
R1 is absent or is chosen from hydrogen, C1-C6 alkyl groups, C1-C6 alkylalkoxy groups, C1-C6 alkylamino groups, C1-C6 alkylcarboxylic acid groups, C1-C6 alkylhydroxy groups, C3-C8 cycloalkyl groups, benzyl groups, C3-C8 heterocyclyl groups, —O—C(═O)—(C1-C6 alkyl) groups, and -CD3;
R3 is chosen from hydrogen, C1-C6 alkyl groups, C1-C6 alkylalkoxy groups, C1-C6 alkylamino groups, C1-C6 alkylcarboxylic acid groups, C1-C6 alkylhydroxy groups, C3-C8 cycloalkyl groups, benzyl groups, C3-C8 heterocyclyl groups, and —O—C(═O)—(C1-C6 alkyl) groups;
R4 is chosen from hydrogen, hydroxyl groups, —O—(C1-C6 alkyl) groups, —O—C(═O)—(C1-C6 alkyl) groups, and C1-C6 alkyl groups; and
R10 is chosen from 3 to 10 membered carbocycles and 3 to 10 membered heterocycles, each of which is substituted with 0 to 3 R8,
wherein each Ra is independently chosen from halogens, C1-C6 alkyl groups, —O—(C1-C6)alkyl groups, C1-C6 alkylalkoxy groups, C1-C6 alkylhydroxy groups, -S(═O)w-(4 to 7 membered heterocycles) wherein w is 1 or 2, 4 to 7 membered carbocycles, hydroxyl groups, -NR15R16, C3-C8 cycloalkyl groups, benzyl groups, and C3-C8 heterocyclyl groups,
wherein each R8 is independently substituted with 0 to 3 groups independently chosen from halogens, hydroxyl groups, -NR15R16, C1-C6 alkyl groups, -(C═O)—(C1-C6 alkyl) groups, -(C═O)—(C1-C6 alkyl)(C3-C10 heterocyclyl groups), -S(═O)w-(C3-C8 heterocyclyl) groups wherein w is 0, 1, or 2, and C1-C6 alkylcarboxylic acid groups, each of which is substituted with 0, 1, or 2 groups independently chosen from halogens, hydroxyl groups, -NR15R16, and C1-C3 alkyl groups;

R15 and R16 are each independently chosen from hydrogen, R17, -C(═O)-R17, and —C(═O)—O-R17, wherein R17 is chosen from hydrogen, C1-C6 alkyl groups, C3-C8 cycloalkyl groups, benzyl groups, and C3-C8 heterocyclyl groups;
wherein R1, R3, R4, R15, R16, and R17 are each independently substituted with 0 to 3 groups independently chosen from halogens, hydroxyl groups, C1-C6 alkyl groups, —O—(C1-C6 alkyl) groups, -NR15R16, C3-C8 cycloalkyl groups, C1-C6 alkylhydroxy groups, C1-C6 alkylalkoxy groups, benzyl groups, and C3-C8 heterocyclyl groups; and
L is a linker comprising at least one cleavable peptide moiety.